On the public citation graph
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
0 signed · 1305 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-aopenalex-snapshot
The National Comprehensive Cancer Network
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19980815)83:4<719::aid-cncr13>3.0.co;2-vopenalex-snapshot
A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19990215)85:4<855::aid-cncr12>3.0.co;2-ropenalex-snapshot
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma
inferredcites →https://doi.org/10.1002/1097-0142(20010401)91:7<1316::aid-cncr1134>3.0.co;2-0openalex-snapshot
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma
inferredcites →https://doi.org/10.1002/1097-0142(20010615)91:12<2246::aid-cncr1255>3.0.co;2-4openalex-snapshot
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
inferredcites →https://doi.org/10.1002/1097-0142(20010801)92:3<601::aid-cncr1360>3.0.co;2-kopenalex-snapshot
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma
inferredcites →https://doi.org/10.1002/14651858.cd003189.pub4openalex-snapshot
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma
inferredcites →https://doi.org/10.1002/14651858.cd007107.pub2openalex-snapshot
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
inferredcites →https://doi.org/10.1002/cncr.11827openalex-snapshot
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma
inferredcites →https://doi.org/10.1002/cncr.21847openalex-snapshot
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
inferredcites →https://doi.org/10.1002/cncr.22939openalex-snapshot
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
inferredcites →https://doi.org/10.1002/cncr.24774openalex-snapshot
The impact of health insurance status on the survival of patients with head and neck cancer
inferredcites →https://doi.org/10.1002/cncr.24861openalex-snapshot
Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer
inferredcites →https://doi.org/10.1007/s00277-007-0399-yopenalex-snapshot
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP
inferredcites →https://doi.org/10.1007/s00280-002-0449-zopenalex-snapshot
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)
inferredcites →https://doi.org/10.1007/s00520-006-0201-zopenalex-snapshot
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
inferredcites →https://doi.org/10.1007/s00520-007-0270-7openalex-snapshot
Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy–Neutropenia (FACT-N)
inferredcites →https://doi.org/10.1007/s00520-007-0347-3openalex-snapshot
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
inferredcites →https://doi.org/10.1007/s00520-008-0430-4openalex-snapshot
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
inferredcites →https://doi.org/10.1007/s00520-010-0840-yopenalex-snapshot
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study
inferredcites →https://doi.org/10.1007/s10549-008-0018-1openalex-snapshot
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
inferredcites →https://doi.org/10.1016/0959-8049(93)90376-qopenalex-snapshot
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
inferredcites →https://doi.org/10.1016/j.biopha.2005.06.008openalex-snapshot
Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications
inferredcites →https://doi.org/10.1016/j.critrevonc.2006.12.007openalex-snapshot
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
inferredcites →https://doi.org/10.1016/j.critrevonc.2010.03.008openalex-snapshot
Febrile neutropenia: A critical review of the initial management
inferredcites →https://doi.org/10.1016/j.ejca.2005.03.006openalex-snapshot
Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: A systematic review of randomised controlled trials
inferredcites →https://doi.org/10.1016/j.ejca.2006.05.002openalex-snapshot
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
inferredcites →https://doi.org/10.1016/j.ejca.2006.07.012openalex-snapshot
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
inferredcites →https://doi.org/10.1016/j.ejca.2008.11.021openalex-snapshot
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
inferredcites →https://doi.org/10.1016/j.ejon.2008.10.003openalex-snapshot
Docetaxel-related side effects and their management
inferredcites →https://doi.org/10.1016/j.lungcan.2007.10.001openalex-snapshot
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.ygyno.2003.09.021openalex-snapshot
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients A Hellenic Cooperative Oncology Group Study
inferredcites →https://doi.org/10.1016/j.ygyno.2004.05.021openalex-snapshot
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer
inferredcites →https://doi.org/10.1016/s0002-9343(02)01036-7openalex-snapshot
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis
inferredcites →https://doi.org/10.1016/s0093-7754(03)00314-2openalex-snapshot
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia
inferredcites →https://doi.org/10.1016/s0140-6736(00)02034-1openalex-snapshot
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
inferredcites →https://doi.org/10.1016/s0140-6736(07)61125-8openalex-snapshot
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(09)60569-9openalex-snapshot
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
inferredcites →https://doi.org/10.1016/s0959-8049(01)00068-5openalex-snapshot
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
inferredcites →https://doi.org/10.1016/s0959-8049(03)00662-2openalex-snapshot
EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer
inferredcites →https://doi.org/10.1016/s0959-8049(97)10039-9openalex-snapshot
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor
inferredcites →https://doi.org/10.1016/s0959-8049(99)00259-2openalex-snapshot
Chemotherapy dose reduction and delay in clinical practice
inferredcites →https://doi.org/10.1016/s1040-1741(08)79037-7openalex-snapshot
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(07)70041-4openalex-snapshot
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
inferredcites →https://doi.org/10.1023/a:1012545507920openalex-snapshot
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study
inferredcites →https://doi.org/10.1023/a:1026418831238openalex-snapshot
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6600641openalex-snapshot
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6601618openalex-snapshot
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6601676openalex-snapshot
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
inferredcites →https://doi.org/10.1038/sj.bjc.6601708openalex-snapshot
Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?
inferredcites →https://doi.org/10.1038/sj.bjc.6602172openalex-snapshot
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6602412openalex-snapshot
An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital
inferredcites →https://doi.org/10.1038/sj.bjc.6602514openalex-snapshot
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
inferredcites →https://doi.org/10.1038/sj.bjc.6603085openalex-snapshot
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6603133openalex-snapshot
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
inferredcites →https://doi.org/10.1038/sj.bjc.6604026openalex-snapshot
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group
inferredcites →https://doi.org/10.1038/sj.bjc.6604468openalex-snapshot
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma
inferredcites →https://doi.org/10.1038/sj.bjc.6604862openalex-snapshot
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6605270openalex-snapshot
Prevention of febrile neutropenia: use of prophylactic antibiotics
inferredcites →https://doi.org/10.1038/sj.bjc.6605272openalex-snapshot
Management of chemotherapy-associated febrile neutropenia
inferredcites →https://doi.org/10.1038/sj.bjc.6605273openalex-snapshot
Impact of effective prevention and management of febrile neutropenia
inferredcites →https://doi.org/10.1056/nejm199107183250305openalex-snapshot
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejm199405053301801openalex-snapshot
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
inferredcites →https://doi.org/10.1056/nejm199407143310226openalex-snapshot
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
inferredcites →https://doi.org/10.1056/nejm199504063321401openalex-snapshot
Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
inferredcites →https://doi.org/10.1056/nejm200009283431302openalex-snapshot
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa011954openalex-snapshot
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa022473openalex-snapshot
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
inferredcites →https://doi.org/10.1056/nejmoa032691openalex-snapshot
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa044097openalex-snapshot
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
inferredcites →https://doi.org/10.1056/nejmoa050078openalex-snapshot
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
inferredcites →https://doi.org/10.1056/nejmoa061884openalex-snapshot
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa073149openalex-snapshot
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
inferredcites →https://doi.org/10.1080/10428190210177openalex-snapshot
Primary Treatment of Low-grade Non-Hodgkin's Lymphoma with the Combination of Fludarabine and Mitoxantrone: A Phase II Study of the Hellenic Cooperative Oncology Group
inferredcites →https://doi.org/10.1080/1042819031000067981openalex-snapshot
ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1080/1042819031000103953openalex-snapshot
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1080/1042819031000119262openalex-snapshot
Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy
inferredcites →https://doi.org/10.1080/10428190902756081openalex-snapshot
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
inferredcites →https://doi.org/10.1086/339215openalex-snapshot
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
inferredcites →https://doi.org/10.1093/annonc/mdf130openalex-snapshot
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
inferredcites →https://doi.org/10.1093/annonc/mdf222openalex-snapshot
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
inferredcites →https://doi.org/10.1093/annonc/mdg019openalex-snapshot
A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
inferredcites →https://doi.org/10.1093/annonc/mdg109openalex-snapshot
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
inferredcites →https://doi.org/10.1093/annonc/mdg118openalex-snapshot
Docetaxel and carboplatin is an active regimen in advancednon-small-cell lung cancer: a phase II study in Caucasian and Asian patients
inferredcites →https://doi.org/10.1093/annonc/mdg703openalex-snapshot
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease
inferredcites →https://doi.org/10.1093/annonc/mdi023openalex-snapshot
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
inferredcites →https://doi.org/10.1093/annonc/mdi264openalex-snapshot
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
inferredcites →https://doi.org/10.1093/annonc/mdj995openalex-snapshot
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
inferredcites →https://doi.org/10.1093/annonc/mdl135openalex-snapshot
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
inferredcites →https://doi.org/10.1093/annonc/mdl321openalex-snapshot
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study
inferredcites →https://doi.org/10.1093/annonc/mdl355openalex-snapshot
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
inferredcites →https://doi.org/10.1093/annonc/mdl401openalex-snapshot
Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVAR Germany
inferredcites →https://doi.org/10.1093/annonc/mdm052openalex-snapshot
Hematopoietic growth factors: ESMO Recommendations for the application
inferredcites →https://doi.org/10.1093/annonc/mdm438openalex-snapshot
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
inferredcites →https://doi.org/10.1093/annonc/mdm539openalex-snapshot
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
inferredcites →https://doi.org/10.1093/annonc/mdn560openalex-snapshot
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer
inferredcites →https://doi.org/10.1093/annonc/mdn655openalex-snapshot
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
inferredcites →https://doi.org/10.1093/annonc/mdp162openalex-snapshot
Hematopoietic growth factors: ESMO Recommendations for the applications
inferredcites →https://doi.org/10.1093/annonc/mdp574openalex-snapshot
Development of a new G-CSF product based on biosimilarity assessment
inferredcites →https://doi.org/10.1093/annonc/mdq195openalex-snapshot
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
inferredcites →https://doi.org/10.1093/jnci/90.16.1205openalex-snapshot
Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
inferredcites →https://doi.org/10.1093/jnci/93.1.31openalex-snapshot
Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial
inferredcites →https://doi.org/10.1093/jnci/djg036openalex-snapshot
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
inferredcites →https://doi.org/10.1093/jnci/dji114openalex-snapshot
Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1093/jnci/djk028openalex-snapshot
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
inferredcites →https://doi.org/10.1093/jnci/djk057openalex-snapshot
Granulocyte Colony-Stimulating Factor: Key (F)actor or Innocent Bystander in the Development of Secondary Myeloid Malignancy?
inferredcites →https://doi.org/10.1093/jnci/djp007openalex-snapshot
Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
inferredcites →https://doi.org/10.1093/oxfordjournals.annonc.a058364openalex-snapshot
E-SHAP: Inadequate treatment for poor-prognosis recurrent lymphoma
inferredcites →https://doi.org/10.1093/oxfordjournals.annonc.a058619openalex-snapshot
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol
inferredcites →https://doi.org/10.1097/00000421-200008000-00017openalex-snapshot
Lenograstim as Support for ACE Chemotherapy of Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1097/00000421-200108000-00001openalex-snapshot
CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer
inferredcites →https://doi.org/10.1097/00002820-200505000-00001openalex-snapshot
Quality of Life and Chemotherapy-induced Neutropenia
inferredcites →https://doi.org/10.1097/01.coc.0000020581.59835.7aopenalex-snapshot
Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1097/coc.0b013e318165c01dopenalex-snapshot
Identifying Patients at High Risk for Neutropenic Complications During Chemotherapy for Metastatic Breast Cancer With Doxorubicin or Pegylated Liposomal Doxorubicin
inferredcites →https://doi.org/10.1097/coc.0b013e31817be954openalex-snapshot
Multicenter Randomized Open-Label Phase III Study Comparing Efficacy, Safety, and Tolerability of Conventional Carboplatin Plus Etoposide Versus Dose-Intensified Carboplatin Plus Etoposide Plus Lenograstim in Small-Cell Lung Cancer in “Extensive Disease” Stage
inferredcites →https://doi.org/10.1097/jto.0b013e318186fb0dopenalex-snapshot
Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
inferredcites →https://doi.org/10.1097/jto.0b013e3181a52964openalex-snapshot
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
inferredcites →https://doi.org/10.1111/j.1365-2141.2006.06438.xopenalex-snapshot
Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study
inferredcites →https://doi.org/10.1111/j.1365-2141.2008.07514.xopenalex-snapshot
Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study
inferredcites →https://doi.org/10.1111/j.1365-2354.2007.00797.xopenalex-snapshot
Impact of neutropenia on delivering planned chemotherapy for solid tumours
inferredcites →https://doi.org/10.1111/j.1365-2354.2008.00959.xopenalex-snapshot
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
inferredcites →https://doi.org/10.1111/j.1600-0609.2007.00996.xopenalex-snapshot
GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study
inferredcites →https://doi.org/10.1159/000066768openalex-snapshot
Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients
inferredcites →https://doi.org/10.1159/000086778openalex-snapshot
Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Prognosis in Extensive Disease Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1159/000232580openalex-snapshot
Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma
inferredcites →https://doi.org/10.1177/030089169408000609openalex-snapshot
The Role of Granulocyte Colony-Stimulating Factor (Filgrastim) in Maintaining Dose Intensity during Conventional-Dose Chemotherapy with Abvd in Hodgkin's Disease
inferredcites →https://doi.org/10.1179/joc.2003.15.2.184openalex-snapshot
Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma
inferredcites →https://doi.org/10.1182/blood-2002-10-3238openalex-snapshot
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
inferredcites →https://doi.org/10.1182/blood-2003-06-2094openalex-snapshot
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
inferredcites →https://doi.org/10.1182/blood-2003-06-2095openalex-snapshot
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
inferredcites →https://doi.org/10.1182/blood-2006-07-035709openalex-snapshot
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
inferredcites →https://doi.org/10.1182/blood-2008-02-140582openalex-snapshot
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
inferredcites →https://doi.org/10.1182/blood-2008-03-147025openalex-snapshot
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
inferredcites →https://doi.org/10.1182/blood.v112.11.3605.3605openalex-snapshot
Importance of Relative Dose Intensity for Survival in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-Like Regimen
inferredcites →https://doi.org/10.1182/blood.v112.11.4931.4931openalex-snapshot
The Impact of Relative Dose Intensity of Rituximab-CHOP on Survival in Diffuse Large B-Cell Lymphoma Patients
inferredcites →https://doi.org/10.1182/blood.v114.22.406.406openalex-snapshot
R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study.
inferredcites →https://doi.org/10.1182/blood.v114.22.535.535openalex-snapshot
First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of…
inferredcites →https://doi.org/10.1182/blood.v80.6.1430.1430openalex-snapshot
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
inferredcites →https://doi.org/10.1185/030079907x219599openalex-snapshot
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.1186/1471-2407-8-332openalex-snapshot
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
inferredcites →https://doi.org/10.1200/jco.1988.6.9.1377openalex-snapshot
A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.
inferredcites →https://doi.org/10.1200/jco.1990.8.6.963openalex-snapshot
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
inferredcites →https://doi.org/10.1200/jco.1994.12.6.1169openalex-snapshot
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
inferredcites →https://doi.org/10.1200/jco.1995.13.10.2629openalex-snapshot
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
inferredcites →https://doi.org/10.1200/jco.1995.13.11.2688openalex-snapshot
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
inferredcites →https://doi.org/10.1200/jco.1995.13.11.2700openalex-snapshot
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
inferredcites →https://doi.org/10.1200/jco.1995.13.3.652openalex-snapshot
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
inferredcites →https://doi.org/10.1200/jco.1995.13.7.1564openalex-snapshot
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
inferredcites →https://doi.org/10.1200/jco.1996.14.12.3056openalex-snapshot
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
inferredcites →https://doi.org/10.1200/jco.1996.14.2.619openalex-snapshot
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
inferredcites →https://doi.org/10.1200/jco.1997.15.4.1427openalex-snapshot
Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma.
inferredcites →https://doi.org/10.1200/jco.1998.16.1.255openalex-snapshot
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen.
inferredcites →https://doi.org/10.1200/jco.1998.16.2.716openalex-snapshot
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
inferredcites →https://doi.org/10.1200/jco.1998.16.6.2126openalex-snapshot
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
inferredcites →https://doi.org/10.1200/jco.1998.16.7.2459openalex-snapshot
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
inferredcites →https://doi.org/10.1200/jco.1998.16.8.2651openalex-snapshot
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
inferredcites →https://doi.org/10.1200/jco.1998.16.9.2930openalex-snapshot
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
inferredcites →https://doi.org/10.1200/jco.1999.17.1.12openalex-snapshot
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.1999.17.2.658openalex-snapshot
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.1999.17.9.2676openalex-snapshot
Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
inferredcites →https://doi.org/10.1200/jco.20.3.727openalex-snapshot
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2000.18.12.2385openalex-snapshot
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
inferredcites →https://doi.org/10.1200/jco.2000.18.14.2733openalex-snapshot
Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma
inferredcites →https://doi.org/10.1200/jco.2000.18.16.3038openalex-snapshot
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients
inferredcites →https://doi.org/10.1200/jco.2000.18.2.395openalex-snapshot
Improving Survival Without Reducing Quality of Life in Small-Cell Lung Cancer Patients by Increasing the Dose-Intensity of Chemotherapy With Granulocyte Colony-Stimulating Factor Support: Results of a British Medical Research Council Multicenter Randomized Trial
inferredcites →https://doi.org/10.1200/jco.2000.18.20.3558openalex-snapshot
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
inferredcites →https://doi.org/10.1200/jco.2001.19.10.2638openalex-snapshot
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of…
inferredcites →https://doi.org/10.1200/jco.2001.19.13.3210openalex-snapshot
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
inferredcites →https://doi.org/10.1200/jco.2001.19.3.612openalex-snapshot
Intensification of Adjuvant Chemotherapy: 5-Year Results of a Randomized Trial Comparing Conventional Doxorubicin and Cyclophosphamide With High-Dose Mitoxantrone and Cyclophosphamide With Filgrastim in Operable Breast Cancer With 10 or More Involved Axillary Nodes
inferredcites →https://doi.org/10.1200/jco.2001.19.6.1707openalex-snapshot
Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial
inferredcites →https://doi.org/10.1200/jco.2002.02.021openalex-snapshot
Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients
inferredcites →https://doi.org/10.1200/jco.2002.02.068openalex-snapshot
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2002.02.069openalex-snapshot
Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923
inferredcites →https://doi.org/10.1200/jco.2002.09.002openalex-snapshot
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
inferredcites →https://doi.org/10.1200/jco.2002.11.005openalex-snapshot
Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2003.03.040openalex-snapshot
Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma
inferredcites →https://doi.org/10.1200/jco.2003.04.040openalex-snapshot
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2003.05.135openalex-snapshot
Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study
inferredcites →https://doi.org/10.1200/jco.2003.08.058openalex-snapshot
Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2003.09.081openalex-snapshot
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
inferredcites →https://doi.org/10.1200/jco.2003.10.082openalex-snapshot
Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study
inferredcites →https://doi.org/10.1200/jco.2003.12.046openalex-snapshot
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
inferredcites →https://doi.org/10.1200/jco.2004.00.7955openalex-snapshot
Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study
inferredcites →https://doi.org/10.1200/jco.2004.01.140openalex-snapshot
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803
inferredcites →https://doi.org/10.1200/jco.2004.03.213openalex-snapshot
Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study
inferredcites →https://doi.org/10.1200/jco.2004.05.188openalex-snapshot
Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2004.06.070openalex-snapshot
Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713
inferredcites →https://doi.org/10.1200/jco.2004.07.184openalex-snapshot
Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
inferredcites →https://doi.org/10.1200/jco.2004.08.125openalex-snapshot
Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.6125openalex-snapshot
Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.776openalex-snapshot
Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): Results from a prospective nationwide registry
inferredcites →https://doi.org/10.1200/jco.2005.02.907openalex-snapshot
ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi
inferredcites →https://doi.org/10.1200/jco.2005.03.099openalex-snapshot
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
inferredcites →https://doi.org/10.1200/jco.2005.05.078openalex-snapshot
Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group
inferredcites →https://doi.org/10.1200/jco.2005.05.645openalex-snapshot
Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials
inferredcites →https://doi.org/10.1200/jco.2005.09.071openalex-snapshot
Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732
inferredcites →https://doi.org/10.1200/jco.2005.09.102openalex-snapshot
First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
inferredcites →https://doi.org/10.1200/jco.2006.06.4451openalex-snapshot
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
inferredcites →https://doi.org/10.1200/jco.2006.06.8429openalex-snapshot
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
showing the first 200 of 233 · page through all 233
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4861052openalex-extracted
An Open-Label, Randomized Phase III Study of Telpegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.2139/ssrn.5116048openalex-extracted
Comparative Long and Short-Term Efficacy and Safety of Pertuzumab Plus Trastuzumab Versus Trastuzumab Monotherapy in Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis of Six Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1001/jamadermatol.2013.7452openalex-snapshot
Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France
inferred← citeshttps://doi.org/10.1001/jamainternmed.2013.2921openalex-snapshot
Deviations From Guideline-Based Therapy for Febrile Neutropenia in Cancer Patients and Their Effect on Outcomes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.38191openalex-snapshot
Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing
inferred← citeshttps://doi.org/10.1001/jamaoncol.2023.4255openalex-snapshot
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.1002/14651858.cd007913.pub2openalex-snapshot
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
inferred← citeshttps://doi.org/10.1002/14651858.cd015656openalex-snapshot
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of solid tumors
inferred← citeshttps://doi.org/10.1002/9781118674826.ch25openalex-snapshot
Neoadjuvant chemotherapy in the treatment of muscle‐invasive bladder cancer
inferred← citeshttps://doi.org/10.1002/9781118992845.ch11openalex-snapshot
Oncologic emergencies in critical care
inferred← citeshttps://doi.org/10.1002/ajh.24416openalex-snapshot
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM)
inferred← citeshttps://doi.org/10.1002/bcp.70259openalex-snapshot
Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide
inferred← citeshttps://doi.org/10.1002/bimj.201700143openalex-snapshot
Smooth individual level covariates adjustment in disease mapping
inferred← citeshttps://doi.org/10.1002/cam4.1317openalex-snapshot
Risk stratification for febrile neutropenia in patients with testicular germ cell tumors
inferred← citeshttps://doi.org/10.1002/cam4.1388openalex-snapshot
An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer
inferred← citeshttps://doi.org/10.1002/cam4.1580openalex-snapshot
Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia
inferred← citeshttps://doi.org/10.1002/cam4.200openalex-snapshot
Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
inferred← citeshttps://doi.org/10.1002/cam4.3261openalex-snapshot
Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
inferred← citeshttps://doi.org/10.1002/cam4.344openalex-snapshot
G‐CSF utilization rate and prescribing patterns in United States : associations between physician and patient factors and GCSF use
inferred← citeshttps://doi.org/10.1002/cam4.4465openalex-snapshot
Improved risk prediction of chemotherapy‐induced neutropenia—model development and validation with real‐world data
inferred← citeshttps://doi.org/10.1002/cam4.454openalex-snapshot
Assessing patients’ risk of febrile neutropenia: is there a correlation between physician‐assessed risk and model‐predicted risk?
inferred← citeshttps://doi.org/10.1002/cam4.6519openalex-snapshot
Efficacy and safety of pegfilgrastim biosimilar MD ‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
inferred← citeshttps://doi.org/10.1002/cam4.6898openalex-snapshot
Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors
inferred← citeshttps://doi.org/10.1002/cam4.6974openalex-snapshot
Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer
inferred← citeshttps://doi.org/10.1002/cncr.31914openalex-snapshot
Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony‐stimulating factors in older patients with non‐Hodgkin lymphoma
inferred← citeshttps://doi.org/10.1002/cpdd.1005openalex-snapshot
Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
inferred← citeshttps://doi.org/10.1002/hon.2371openalex-snapshot
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice
inferred← citeshttps://doi.org/10.1002/hon.2734openalex-snapshot
Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study
inferred← citeshttps://doi.org/10.1002/ijc.29046openalex-snapshot
Granulocyte colony‐stimulating factor off‐target effect on nerve outgrowth promotes prostate cancer development
inferred← citeshttps://doi.org/10.1002/ijc.32249openalex-snapshot
Development and validation of a cycle‐specific risk score for febrile neutropenia during chemotherapy cycles 2–6 in patients with solid cancers: The CSRFENCE score
inferred← citeshttps://doi.org/10.1002/ijc.34914openalex-snapshot
Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony‐stimulating factor following chemotherapy: Triangulation of evidence using population‐based cohort and Mendelian randomization analyses
inferred← citeshttps://doi.org/10.1002/pds.5332openalex-snapshot
A framework for the use of biological medicines in the free state province, South Africa
inferred← citeshttps://doi.org/10.1002/phar.1409openalex-snapshot
Prophylactic Use of Pegfilgrastim in Patients Treated with a Nitrosourea and Teniposide for Recurrent Glioma
inferred← citeshttps://doi.org/10.1002/pon.4320openalex-snapshot
Avoidant conversations about death by clinicians cause delays in reporting of neutropenic sepsis: Grounded theory study
inferred← citeshttps://doi.org/10.1002/prp2.578openalex-snapshot
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial
inferred← citeshttps://doi.org/10.1007/174_2011_271openalex-snapshot
Hematological Toxicity in Lung Cancer
inferred← citeshttps://doi.org/10.1007/174_2022_335openalex-snapshot
Hematological Toxicity in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-0-85729-787-7_9openalex-snapshot
Bone Marrow Toxicity: White Blood Cells
inferred← citeshttps://doi.org/10.1007/978-0-85729-999-4_14openalex-snapshot
Clinical Management of Elderly Patients’ Metastatic Prostate Cancer: Other Treatments and Supportive Care
inferred← citeshttps://doi.org/10.1007/978-1-4471-2837-3_9openalex-snapshot
The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma
inferred← citeshttps://doi.org/10.1007/978-1-4614-5438-0openalex-snapshot
Pathobiology of Cancer Regimen-Related Toxicities
inferred← citeshttps://doi.org/10.1007/978-1-4614-6486-0_18openalex-snapshot
Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents
inferred← citeshttps://doi.org/10.1007/978-1-4939-1145-5_23openalex-snapshot
Adjuvant Chemotherapy in Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-1-62703-408-1_11openalex-snapshot
Diffuse Large B-Cell Lymphoma
inferred← citeshttps://doi.org/10.1007/978-1-907673-70-2_2openalex-snapshot
Prevention of Febrile Neutropenia
inferred← citeshttps://doi.org/10.1007/978-1-907673-70-2_7openalex-snapshot
Costs Associated with Febrile Neutropenia
inferred← citeshttps://doi.org/10.1007/978-3-030-00710-2_24openalex-snapshot
Hematopoietic Growth Factors
inferred← citeshttps://doi.org/10.1007/978-3-030-22009-9_771openalex-snapshot
Quality of Life in Older Patients with Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-57949-4_1openalex-snapshot
Cancer Immunotherapy Confers a Global Benefit
inferred← citeshttps://doi.org/10.1007/978-3-030-65403-0_14openalex-snapshot
Management of PTLD After HSCT
inferred← citeshttps://doi.org/10.1007/978-3-030-73234-9_17openalex-snapshot
The Effects of Curcumin on the Side Effects of Anticancer Drugs in Chemotherapy: A Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1007/978-3-031-17273-1_10openalex-snapshot
Oncologic Emergencies in Patients Undergoing Major Surgery
inferred← citeshttps://doi.org/10.1007/978-3-031-30023-3_17openalex-snapshot
Hematopoietic Growth Factors
inferred← citeshttps://doi.org/10.1007/978-3-0348-0218-5_12openalex-snapshot
Using rHuG-CSF in Multiple Myeloma: Consolidated Data, Evolutions, and New Concepts
inferred← citeshttps://doi.org/10.1007/978-3-319-20317-1_13-1openalex-snapshot
Cancer in Older Adults
inferred← citeshttps://doi.org/10.1007/978-3-319-43011-9_62openalex-snapshot
G-CSF and GM-CSF: Clinical Applications in Reproductive Medicine
inferred← citeshttps://doi.org/10.1007/978-3-319-48848-6_58openalex-snapshot
Emergencies in Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-56673-3_42openalex-snapshot
Breast Cancer in Special Groups: Breast Cancer in Pregnancy
inferred← citeshttps://doi.org/10.1007/978-3-319-69892-2_771-1openalex-snapshot
Quality of in Older Patients with Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-70253-7_16openalex-snapshot
Bone Marrow Toxicity: White Blood Cells
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_97-2openalex-snapshot
What the Intensivists Need to Know About Critically Ill Lymphoma Patients
inferred← citeshttps://doi.org/10.1007/978-3-642-24837-5_5openalex-snapshot
Nebenwirkungen und Supportivtherapie
inferred← citeshttps://doi.org/10.1007/978-3-642-25066-8_23openalex-snapshot
Wechselwirkungen zwischen onkologischer Medikation und körperlicher Aktivität
inferred← citeshttps://doi.org/10.1007/978-3-642-39940-4_122openalex-snapshot
Supportivtherapie in der Uroonkologie
inferred← citeshttps://doi.org/10.1007/978-3-642-41168-7_122-1openalex-snapshot
Supportivtherapie in der Uroonkologie
inferred← citeshttps://doi.org/10.1007/978-3-662-44317-0_15openalex-snapshot
Hematopoietic Growth Factors
inferred← citeshttps://doi.org/10.1007/978-3-662-46410-6_1openalex-snapshot
Cancer Immunotherapy Confers a Global Benefit
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_397-1openalex-snapshot
Granulozyten-Kolonie-stimulierender Faktor (G-CSF) zur Prophylaxe der Neutropenie und febrilen Neutropenie bei antineoplastischer Therapie
inferred← citeshttps://doi.org/10.1007/978-3-662-48727-3_6openalex-snapshot
Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie
inferred← citeshttps://doi.org/10.1007/978-3-662-49083-9_6-1openalex-snapshot
Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie
inferred← citeshttps://doi.org/10.1007/978-3-662-53955-2_26openalex-snapshot
Knochenmarksuppression: Granulozytopenie, Thrombozytopenie, Anämie
inferred← citeshttps://doi.org/10.1007/978-3-662-54652-9_26-1openalex-snapshot
Prophylaxe und Therapie von Komplikationen der systemischen Tumortherapie
inferred← citeshttps://doi.org/10.1007/978-3-662-67417-8_26openalex-snapshot
Knochenmarksuppression: Granulozytopenie, Thrombozytopenie, Anämie
inferred← citeshttps://doi.org/10.1007/978-94-024-0844-7_10openalex-snapshot
Complications of Anticancer Drugs and Their Management
inferred← citeshttps://doi.org/10.1007/978-981-97-7316-9_16openalex-snapshot
Beyond PEGylation “PEGylation and its Alternatives”
inferred← citeshttps://doi.org/10.1007/s00120-018-0607-5openalex-snapshot
Onkologische Notfälle in der Chemotherapie
inferred← citeshttps://doi.org/10.1007/s00120-018-0680-9openalex-snapshot
Advanced Prostate Cancer Consensus Conference 2017
inferred← citeshttps://doi.org/10.1007/s00120-022-01831-6openalex-snapshot
G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung
inferred← citeshttps://doi.org/10.1007/s00129-011-2764-0openalex-snapshot
Supportive Therapie in der gynäkologischen Onkologie
inferred← citeshttps://doi.org/10.1007/s00129-013-3287-7openalex-snapshot
Supportive Therapie und Schmerzbehandlung
inferred← citeshttps://doi.org/10.1007/s00134-015-3965-0openalex-snapshot
Understanding the risk for infection in patients with neutropenia
inferred← citeshttps://doi.org/10.1007/s00216-013-7138-0openalex-snapshot
Top-down MS for rapid methionine oxidation site assignment in filgrastim
inferred← citeshttps://doi.org/10.1007/s00228-017-2365-5openalex-snapshot
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients
inferred← citeshttps://doi.org/10.1007/s00277-013-1698-0openalex-snapshot
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors
inferred← citeshttps://doi.org/10.1007/s00277-013-1867-1openalex-snapshot
Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
inferred← citeshttps://doi.org/10.1007/s00277-014-2093-1openalex-snapshot
A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma
inferred← citeshttps://doi.org/10.1007/s00277-014-2250-6openalex-snapshot
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial
inferred← citeshttps://doi.org/10.1007/s00277-017-3191-7openalex-snapshot
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
inferred← citeshttps://doi.org/10.1007/s00277-019-03631-zopenalex-snapshot
Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
inferred← citeshttps://doi.org/10.1007/s00277-019-03901-wopenalex-snapshot
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
inferred← citeshttps://doi.org/10.1007/s00277-023-05411-2openalex-snapshot
Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP
inferred← citeshttps://doi.org/10.1007/s00277-025-06602-9openalex-snapshot
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
inferred← citeshttps://doi.org/10.1007/s00280-011-1769-7openalex-snapshot
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
inferred← citeshttps://doi.org/10.1007/s00280-015-2703-1openalex-snapshot
First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
inferred← citeshttps://doi.org/10.1007/s00280-015-2731-xopenalex-snapshot
Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe
inferred← citeshttps://doi.org/10.1007/s00280-017-3324-7openalex-snapshot
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum
inferred← citeshttps://doi.org/10.1007/s00280-017-3366-xopenalex-snapshot
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
inferred← citeshttps://doi.org/10.1007/s00280-019-03943-xopenalex-snapshot
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00280-020-04063-7openalex-snapshot
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer
inferred← citeshttps://doi.org/10.1007/s00280-020-04118-9openalex-snapshot
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
inferred← citeshttps://doi.org/10.1007/s00280-021-04395-yopenalex-snapshot
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach
inferred← citeshttps://doi.org/10.1007/s00280-026-04966-xopenalex-snapshot
Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders
inferred← citeshttps://doi.org/10.1007/s00285-016-1051-zopenalex-snapshot
Response of an oscillatory differential delay equation to a single stimulus
inferred← citeshttps://doi.org/10.1007/s00403-015-1545-3openalex-snapshot
rhCSF3 accelerates the proliferation of human melanocytes in culture through binding CSF3R and the expression of CSF3R transcripts
inferred← citeshttps://doi.org/10.1007/s00432-018-2643-3openalex-snapshot
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim
inferred← citeshttps://doi.org/10.1007/s00508-012-0185-2openalex-snapshot
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer
inferred← citeshttps://doi.org/10.1007/s00508-015-0917-1openalex-snapshot
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy
inferred← citeshttps://doi.org/10.1007/s00508-023-02300-6openalex-snapshot
Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment
inferred← citeshttps://doi.org/10.1007/s00520-011-1306-6openalex-snapshot
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s00520-011-1375-6openalex-snapshot
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00520-012-1589-2openalex-snapshot
Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis
inferred← citeshttps://doi.org/10.1007/s00520-013-1768-9openalex-snapshot
Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas
inferred← citeshttps://doi.org/10.1007/s00520-013-1873-9openalex-snapshot
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer
inferred← citeshttps://doi.org/10.1007/s00520-013-1911-7openalex-snapshot
Clinical experience with Zarzio® in Europe: what have we learned?
inferred← citeshttps://doi.org/10.1007/s00520-013-2021-2openalex-snapshot
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
inferred← citeshttps://doi.org/10.1007/s00520-013-2067-1openalex-snapshot
Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia
inferred← citeshttps://doi.org/10.1007/s00520-014-2121-7openalex-snapshot
Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy
inferred← citeshttps://doi.org/10.1007/s00520-014-2184-5openalex-snapshot
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma
inferred← citeshttps://doi.org/10.1007/s00520-014-2237-9openalex-snapshot
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen
inferred← citeshttps://doi.org/10.1007/s00520-014-2270-8openalex-snapshot
Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study
inferred← citeshttps://doi.org/10.1007/s00520-014-2318-9openalex-snapshot
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment
inferred← citeshttps://doi.org/10.1007/s00520-014-2328-7openalex-snapshot
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s00520-014-2449-zopenalex-snapshot
A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-014-2457-zopenalex-snapshot
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review
inferred← citeshttps://doi.org/10.1007/s00520-014-2459-xopenalex-snapshot
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia
inferred← citeshttps://doi.org/10.1007/s00520-014-2530-7openalex-snapshot
Moxibustion for the treatment of chemotherapy-induced leukopenia: a systematic review of randomized clinical trials
inferred← citeshttps://doi.org/10.1007/s00520-014-2597-1openalex-snapshot
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
inferred← citeshttps://doi.org/10.1007/s00520-015-2608-xopenalex-snapshot
Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-015-2654-4openalex-snapshot
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
inferred← citeshttps://doi.org/10.1007/s00520-015-2686-9openalex-snapshot
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s00520-015-2777-7openalex-snapshot
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies
inferred← citeshttps://doi.org/10.1007/s00520-015-2779-5openalex-snapshot
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy—a representative sample survey in Germany
inferred← citeshttps://doi.org/10.1007/s00520-015-2803-9openalex-snapshot
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study
inferred← citeshttps://doi.org/10.1007/s00520-015-2805-7openalex-snapshot
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
inferred← citeshttps://doi.org/10.1007/s00520-015-2818-2openalex-snapshot
Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study
inferred← citeshttps://doi.org/10.1007/s00520-015-2834-2openalex-snapshot
Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim
inferred← citeshttps://doi.org/10.1007/s00520-015-2861-zopenalex-snapshot
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
inferred← citeshttps://doi.org/10.1007/s00520-015-2907-2openalex-snapshot
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial
inferred← citeshttps://doi.org/10.1007/s00520-015-2944-xopenalex-snapshot
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors
inferred← citeshttps://doi.org/10.1007/s00520-015-2963-7openalex-snapshot
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
inferred← citeshttps://doi.org/10.1007/s00520-015-2986-0openalex-snapshot
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
inferred← citeshttps://doi.org/10.1007/s00520-015-3057-2openalex-snapshot
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor
inferred← citeshttps://doi.org/10.1007/s00520-016-3079-4openalex-snapshot
Granulocyte growth factor use in elderly patients with non-Hodgkin’s lymphoma in the United States: adherence to guidelines and comparative effectiveness
inferred← citeshttps://doi.org/10.1007/s00520-016-3277-0openalex-snapshot
Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies
inferred← citeshttps://doi.org/10.1007/s00520-016-3390-0openalex-snapshot
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR)
inferred← citeshttps://doi.org/10.1007/s00520-016-3429-2openalex-snapshot
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-017-3572-4openalex-snapshot
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study
inferred← citeshttps://doi.org/10.1007/s00520-017-3692-xopenalex-snapshot
Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population
inferred← citeshttps://doi.org/10.1007/s00520-017-3703-yopenalex-snapshot
The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review
inferred← citeshttps://doi.org/10.1007/s00520-017-3747-zopenalex-snapshot
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan
inferred← citeshttps://doi.org/10.1007/s00520-017-3842-1openalex-snapshot
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
inferred← citeshttps://doi.org/10.1007/s00520-017-3861-yopenalex-snapshot
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-017-3959-2openalex-snapshot
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim
inferred← citeshttps://doi.org/10.1007/s00520-018-4074-8openalex-snapshot
Filgrastim use in patients receiving chemotherapy for early-stage breast cancer—a survey of physicians and patients
inferred← citeshttps://doi.org/10.1007/s00520-018-4224-zopenalex-snapshot
Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy
inferred← citeshttps://doi.org/10.1007/s00520-018-4280-4openalex-snapshot
Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution
inferred← citeshttps://doi.org/10.1007/s00520-018-4367-yopenalex-snapshot
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database
inferred← citeshttps://doi.org/10.1007/s00520-018-4399-3openalex-snapshot
Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study
inferred← citeshttps://doi.org/10.1007/s00520-018-4408-6openalex-snapshot
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)
inferred← citeshttps://doi.org/10.1007/s00520-018-4473-xopenalex-snapshot
Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study
inferred← citeshttps://doi.org/10.1007/s00520-018-4481-xopenalex-snapshot
G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey
inferred← citeshttps://doi.org/10.1007/s00520-018-4513-6openalex-snapshot
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study
inferred← citeshttps://doi.org/10.1007/s00520-018-4572-8openalex-snapshot
Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-019-04725-0openalex-snapshot
Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study
inferred← citeshttps://doi.org/10.1007/s00520-019-04780-7openalex-snapshot
Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy
inferred← citeshttps://doi.org/10.1007/s00520-019-04795-0openalex-snapshot
Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma
inferred← citeshttps://doi.org/10.1007/s00520-019-04802-4openalex-snapshot
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)
inferred← citeshttps://doi.org/10.1007/s00520-019-04879-xopenalex-snapshot
Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study
inferred← citeshttps://doi.org/10.1007/s00520-019-05080-wopenalex-snapshot
Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995–2015
inferred← citeshttps://doi.org/10.1007/s00520-019-05112-5openalex-snapshot
Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study
inferred← citeshttps://doi.org/10.1007/s00520-020-05295-2openalex-snapshot
Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
inferred← citeshttps://doi.org/10.1007/s00520-020-05392-2openalex-snapshot
The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective review
inferred← citeshttps://doi.org/10.1007/s00520-020-05603-wopenalex-snapshot
Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00520-020-05711-7openalex-snapshot
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
inferred← citeshttps://doi.org/10.1007/s00520-020-05868-1openalex-snapshot
Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
inferred← citeshttps://doi.org/10.1007/s00520-021-06230-9openalex-snapshot
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients
inferred← citeshttps://doi.org/10.1007/s00520-021-06266-xopenalex-snapshot
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
inferred← citeshttps://doi.org/10.1007/s00520-022-06834-9openalex-snapshot
Difference of compliance rates for the recommendations in Japanese Guideline on Febrile Neutropenia according to respondents’ attributes: the second report on a questionnaire survey among hematology-oncology physicians and surgeons
inferred← citeshttps://doi.org/10.1007/s00520-022-06851-8openalex-snapshot
Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma
inferred← citeshttps://doi.org/10.1007/s00520-022-06967-xopenalex-snapshot
Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy
inferred← citeshttps://doi.org/10.1007/s00520-022-07103-5openalex-snapshot
Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
inferred← citeshttps://doi.org/10.1007/s00520-022-07341-7openalex-snapshot
A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe
inferred← citeshttps://doi.org/10.1007/s00520-022-07343-5openalex-snapshot
Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients
inferred← citeshttps://doi.org/10.1007/s00520-022-07353-3openalex-snapshot
A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany
inferred← citeshttps://doi.org/10.1007/s00520-022-07421-8openalex-snapshot
Afebrile chemotherapy-induced neutropenia: an international survey spots oncologists’ routine clinical practice versus the standard of care and the impact of COVID-19
inferred← citeshttps://doi.org/10.1007/s00520-023-08071-0openalex-snapshot
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
inferred← citeshttps://doi.org/10.1007/s00520-023-08176-6openalex-snapshot
Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial
showing the first 200 of 1072 · page through all 1072
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.